NO20070458L - Aryl-pyridinderivater som 11-Beta-HSD1 inhibitorer - Google Patents

Aryl-pyridinderivater som 11-Beta-HSD1 inhibitorer

Info

Publication number
NO20070458L
NO20070458L NO20070458A NO20070458A NO20070458L NO 20070458 L NO20070458 L NO 20070458L NO 20070458 A NO20070458 A NO 20070458A NO 20070458 A NO20070458 A NO 20070458A NO 20070458 L NO20070458 L NO 20070458L
Authority
NO
Norway
Prior art keywords
beta
aryl
pyridine derivatives
hsd1 inhibitors
hsd1
Prior art date
Application number
NO20070458A
Other languages
English (en)
Norwegian (no)
Inventor
Werner Neidhart
Bernd Kuhn
Alexander Mayweg
Kurt Amrein
Daniel Hunziker
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20070458L publication Critical patent/NO20070458L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/76Nitrogen atoms to which a second hetero atom is attached
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20070458A 2004-07-28 2007-01-24 Aryl-pyridinderivater som 11-Beta-HSD1 inhibitorer NO20070458L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04103639 2004-07-28
PCT/EP2005/007894 WO2006010546A2 (fr) 2004-07-28 2005-07-20 Derives d'aryl-pyridine

Publications (1)

Publication Number Publication Date
NO20070458L true NO20070458L (no) 2007-01-24

Family

ID=35427898

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20070458A NO20070458L (no) 2004-07-28 2007-01-24 Aryl-pyridinderivater som 11-Beta-HSD1 inhibitorer

Country Status (27)

Country Link
US (2) US7528159B2 (fr)
EP (1) EP1789041B1 (fr)
JP (1) JP4690402B2 (fr)
KR (1) KR100926842B1 (fr)
CN (1) CN100589803C (fr)
AR (1) AR049739A1 (fr)
AT (1) ATE400271T1 (fr)
AU (1) AU2005266531B2 (fr)
BR (1) BRPI0513864A (fr)
CA (1) CA2574875C (fr)
DE (1) DE602005008079D1 (fr)
DK (1) DK1789041T3 (fr)
ES (1) ES2309789T3 (fr)
HK (1) HK1105592A1 (fr)
HR (1) HRP20080477T3 (fr)
IL (1) IL180481A (fr)
MX (1) MX2007000789A (fr)
MY (1) MY138941A (fr)
NO (1) NO20070458L (fr)
NZ (1) NZ552398A (fr)
PL (1) PL1789041T3 (fr)
PT (1) PT1789041E (fr)
RU (1) RU2374239C2 (fr)
SI (1) SI1789041T1 (fr)
TW (1) TW200608972A (fr)
WO (1) WO2006010546A2 (fr)
ZA (1) ZA200700181B (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4690402B2 (ja) * 2004-07-28 2011-06-01 エフ.ホフマン−ラ ロシュ アーゲー 11−β−HSD1インヒビターとしてのアリール−ピリジン誘導体
WO2006106423A2 (fr) * 2005-04-07 2006-10-12 Pfizer Inc. Nouveaux composes de derives aminosulfonyles
WO2007092435A2 (fr) * 2006-02-07 2007-08-16 Wyeth Inhibiteurs 11-beta hsd1
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
RU2009108280A (ru) 2006-08-08 2010-09-20 Санофи-Авентис (Fr) Ариламиноарилалкилзамещенные имидазолидин-2,4-дионы, способы их получения, содержащие эти соединения лекарственные средства и их применение
EP2025674A1 (fr) 2007-08-15 2009-02-18 sanofi-aventis Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament
TW201014822A (en) 2008-07-09 2010-04-16 Sanofi Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
US20100022572A1 (en) 2008-07-18 2010-01-28 Kowa Company, Ltd. Novel spiro compound and medicine comprising the same
US8236789B2 (en) 2008-08-29 2012-08-07 Kowa Company, Ltd. 1-adamantyl azetidin-2-one derivatives and drugs containing same
US8252781B2 (en) 2008-10-29 2012-08-28 Kowa Company, Ltd. 1,2-diazetidin-3-one derivatives and drugs containing same
WO2010068601A1 (fr) 2008-12-08 2010-06-17 Sanofi-Aventis Hydrate de fluoroglycoside hétéroaromatique cristallin, ses procédés de fabrication, ses procédés d'utilisation et compositions pharmaceutiques le contenant
SI2429995T1 (sl) 2009-05-15 2014-05-30 Novartis Ag Arilpiridini kot inhibitorji aldosteron sintaze
JP2013503135A (ja) 2009-08-26 2013-01-31 サノフイ 新規な結晶性複素芳香族フルオログリコシド水和物、その化合物を含んでなる医薬及びその使用
WO2011068927A2 (fr) * 2009-12-04 2011-06-09 Abbott Laboratories Inhibiteurs de la 11-β-hydroxystéroïde déshydrogénase de type 1 (11b-hsd1) et leurs utilisations
WO2011107494A1 (fr) 2010-03-03 2011-09-09 Sanofi Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation
EP2582709B1 (fr) 2010-06-18 2018-01-24 Sanofi Dérivés d'azolopyridin-3-one en tant qu'inhibiteurs de lipases et de phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
US8895547B2 (en) 2011-03-08 2014-11-25 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2012120055A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
US8809324B2 (en) 2011-03-08 2014-08-19 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
EP2683700B1 (fr) 2011-03-08 2015-02-18 Sanofi Dérivés d'oxathiazine tétra-substitués, leur procédé de fabrication, leur utilisation comme médicament ainsi que médicaments en étant pourvu et leur utilisation
EP2683701B1 (fr) 2011-03-08 2014-12-24 Sanofi Dérivés d'oxathiazine substitués par des groupes de benzyle-méthyles ou d'hétéro-méthyles, leur procédé de fabrication, leur utilisation comme médicament ainsi que médicaments en étant pourvu et leur utilisation
WO2012120053A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine ramifiés, procédé pour leur préparation, utilisation en tant que médicament, agents pharmaceutiques contenant ces dérivés et leur utilisation
EP2766349B1 (fr) 2011-03-08 2016-06-01 Sanofi Dérivés d'oxathiazine substitués par des carbocycles ou des hétérocycles, leur procédé de préparation, médicaments contenant ces composés et leur utilisation
WO2012120054A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
WO2012120051A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés benzyl-oxathiazine substitués avec adamantane ou noradamantane, médicaments contenant ces composés et leur utilisation
HUE031585T2 (en) * 2011-03-16 2017-07-28 Mitsubishi Tanabe Pharma Corp Sulfonamide Compounds with TRPM8 Antagonist Activity
WO2013037390A1 (fr) 2011-09-12 2013-03-21 Sanofi Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
WO2013045413A1 (fr) 2011-09-27 2013-04-04 Sanofi Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b] pyridine-4-carboxylique utilisés comme inhibiteurs de kinase
JP6302846B2 (ja) 2012-02-22 2018-03-28 サンフォード−バーンハム メディカル リサーチ インスティテュート Tnap阻害剤としてのスルホンアミド化合物およびその使用
KR20150092162A (ko) * 2012-12-10 2015-08-12 에프. 호프만-라 로슈 아게 RORc 조절인자로서 벤질 설폰아미드 유도체
CN105175323B (zh) * 2015-09-16 2017-12-22 浙江海翔药业股份有限公司 一种制备2‑(4‑乙酰胺基苯磺酰基)胺基吡啶的方法
MX2020008082A (es) * 2018-02-05 2020-09-24 Univ Strasbourg Compuestos y composiciones para el tratamiento del dolor.
MA54133B1 (fr) 2018-03-08 2022-01-31 Incyte Corp Composés d'aminopyrazine diol utilisés comme inhibiteurs de pi3k-y
WO2020010003A1 (fr) 2018-07-02 2020-01-09 Incyte Corporation DÉRIVÉS D'AMINOPYRAZINE UTILISÉS EN TANT QU'INHIBITEURS DE PI3K-γ
KR102418518B1 (ko) * 2020-08-05 2022-07-07 성균관대학교산학협력단 설퍼 일라이드를 이용한 n-헤테로고리의 선택적 알킬화 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703096A (en) * 1994-10-07 1997-12-30 Sankyo Company, Limited Oxime derivatives, their preparation and their therapeutic use
KR20050044517A (ko) * 2001-11-22 2005-05-12 바이오비트럼 에이비 11-베타-히드록시 스테로이드 탈수소효소 유형 1 의억제제
CA2466490C (fr) * 2001-11-22 2009-12-29 Biovitrum Ab Inhibiteurs de la 11-beta-hydroxysteroide deshydrogenase de type 1
WO2004011410A1 (fr) * 2002-07-27 2004-02-05 Astrazeneca Ab Composes chimiques
JP4690402B2 (ja) * 2004-07-28 2011-06-01 エフ.ホフマン−ラ ロシュ アーゲー 11−β−HSD1インヒビターとしてのアリール−ピリジン誘導体

Also Published As

Publication number Publication date
JP4690402B2 (ja) 2011-06-01
WO2006010546A2 (fr) 2006-02-02
KR20070026865A (ko) 2007-03-08
KR100926842B1 (ko) 2009-11-13
MX2007000789A (es) 2007-03-23
BRPI0513864A (pt) 2008-05-20
MY138941A (en) 2009-08-28
IL180481A0 (en) 2007-06-03
AR049739A1 (es) 2006-08-30
US20090149503A1 (en) 2009-06-11
ES2309789T3 (es) 2008-12-16
EP1789041A2 (fr) 2007-05-30
RU2007107189A (ru) 2008-09-10
SI1789041T1 (sl) 2008-10-31
CA2574875C (fr) 2010-09-28
CN100589803C (zh) 2010-02-17
CN1988905A (zh) 2007-06-27
JP2008508212A (ja) 2008-03-21
IL180481A (en) 2011-05-31
US8211913B2 (en) 2012-07-03
WO2006010546A3 (fr) 2006-04-13
EP1789041B1 (fr) 2008-07-09
ZA200700181B (en) 2009-03-25
ATE400271T1 (de) 2008-07-15
NZ552398A (en) 2010-08-27
PL1789041T3 (pl) 2008-11-28
US7528159B2 (en) 2009-05-05
TW200608972A (en) 2006-03-16
US20060025455A1 (en) 2006-02-02
HRP20080477T3 (en) 2008-12-31
PT1789041E (pt) 2008-08-20
AU2005266531B2 (en) 2008-11-20
CA2574875A1 (fr) 2006-02-02
AU2005266531A1 (en) 2006-02-02
DE602005008079D1 (de) 2008-08-21
RU2374239C2 (ru) 2009-11-27
DK1789041T3 (da) 2008-09-08
HK1105592A1 (en) 2008-02-22

Similar Documents

Publication Publication Date Title
NO20070458L (no) Aryl-pyridinderivater som 11-Beta-HSD1 inhibitorer
NO20071617L (no) Indozolonderivater som 11B-HSD1-inhibitorer
NO20091548L (no) Imidazolon- og imidazolidinonderivater som 11B-HSD1 inhibitorer for diabetes
NO20070445L (no) Pyrimidinderivater.
NO20084418L (no) Azolopyridin-3-on derivater som inhibitorer av endoteliallipase
NO20080554L (no) Pyrazolonderivater
NO20082159L (no) Triazolopyridinderivater som inhibitorer av lipaser og fosfolipaser
NO20082388L (no) Heteroaryl substituerte piperidinderivater som L-CPT1 inhibitorer
NO20064077L (no) Kemokinreseptorantagonister
NO20072978L (no) Nye betuinderivater, preparat derav og anvendelse derav
NO20071658L (no) Alkil-pyridiner som 11-beta-inhibitorer for diabetes
NO20054852L (no) GFAT inhibitorer
NO20082389L (no) 2,3,4-trifenylimidazolinderivater som inhibitor av interaksjonen mellom P53- og MDM2-proteiner for anvendelse som antikreftmidler
DK2324008T3 (da) Diarylpyrazol som protein kinase inhibitorer
NO20075059L (no) Nye forbindelser II 2-pyridinderivater som inhibitorer av neutrofil elastase
NO20071137L (no) Nye piperidinderivater for behandling av depresjon
NO20085064L (no) 4,5-difenyl-pyrimidinyl-oksy eller -merkaptosubstituerte karboksylsyrer, fremgangsmate for deres fremstilling og anvendelse derav som medikamenter
MX2010005824A (es) Derivados de aminotiazol.
NO20092723L (no) Indazolylester og amidderivater for behandling av gluccocorticoid reseptormedierte sykdommer
MX2009005691A (es) Inhibidores de la enzima de diacilglicerol o-acilotransferasa tipo i.
NO20085066L (no) 4,5-difenyl-pyrimidinyl-aminosubstituerte karboksylsyrer, fremgangsmate for deres fremstilling og anvendelse derav som medikamenter
TNSN06220A1 (en) Benzimidazole derivatives
NO20081942L (no) Karbamoylbenzotriazolderivater som inhibitorer av lipaser og fosfolipaser
NO20076695L (no) Nye MCHR1-antagonister og deres anvendelse for behandling av MCHR1-medierte tilstander og forstyrrelser
NO20083708L (no) 4-Fenyl-tiazol-5-karboksylsyre og 4-fenyl-tiazol-5-karboksylmider som PLK1-inhibitorer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application